TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $664,367 | -43.5% | 74,314 | -3.0% | 0.08% | -41.4% |
| Q2 2023 | $1,176,806 | -34.6% | 76,615 | -4.3% | 0.14% | -40.6% |
| Q1 2023 | $1,800,325 | +1.9% | 80,050 | -4.7% | 0.24% | -7.2% |
| Q4 2022 | $1,766,036 | -17.7% | 83,977 | -3.6% | 0.26% | -19.1% |
| Q3 2022 | $2,145,000 | +1.5% | 87,068 | -0.2% | 0.32% | +5.5% |
| Q2 2022 | $2,114,000 | -11.5% | 87,266 | -5.8% | 0.31% | +16.2% |
| Q1 2022 | $2,388,000 | -48.4% | 92,653 | -37.8% | 0.26% | -32.2% |
| Q4 2021 | $4,627,000 | +25.7% | 149,077 | -1.8% | 0.39% | +20.7% |
| Q3 2021 | $3,682,000 | +62.8% | 151,839 | -2.0% | 0.32% | +64.5% |
| Q2 2021 | $2,261,000 | -44.6% | 154,968 | -5.1% | 0.20% | -48.2% |
| Q1 2021 | $4,079,000 | +22.6% | 163,371 | +33.8% | 0.38% | +29.7% |
| Q4 2020 | $3,327,000 | – | 122,076 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |